arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Q32 Bio Inc.

QTTB
$10.55 ▲ +0.06 (+0.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
39 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
69
Health
Good
Bullish
auto_awesome

Analytical Summary

Q32 Bio Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $214.6M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -6.8%
FCF / Share $-0.15
Trailing P/E
Price / Book 2.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

39-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↑ +100.0%
Net Income Profit after all expenses
$-7.61M
↑ +31.0%
FCF / Share Free cash flow per share
$-0.15
↑ +66.4%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
63
Returns
98
Cash Quality
10

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 39 quarters